ALDH2/eIF3E Interaction Modulates Protein Translation Critical for Cardiomyocyte Ferroptosis in Acute Myocardial Ischemia Injury

Xin Chen, Xiujian Yu, Xiaodong Xu, Rui Li, Ningning Liang, Lili Zhang, Luxiao Li, Jingyu Zhang, Mingyao Zhou, Tongwei Lv, Haoran Ma, Yongqiang Wang, Yanwen Ye, Chunzhao Yin, Shiting Chen, Hui Huang, Jinwei Tian, Aijun Sun, Weiyuan Wang, Dewen Yan, Pan Li, Huang‐Tian Yang, Shanshan Zhong, Huiyong YinmedRxiv 2024 · DOI

TL;DR

Researchers have discovered that the common ALDH22 genetic variant—carried by nearly 40% of East Asians—exacerbates heart failure after a heart attack by triggering ferroptosis*, a specific type of iron-dependent cell death. The study reveals a novel "non-enzymatic" mechanism where ALDH2 acts as a molecular brake on the translation factor eIF3E; when ALDH2 is deficient, eIF3E ramps up the production of proteins that drive cellular self-destruction.

What Problem Does This Paper Address?

Acute Myocardial Infarction (AMI), or heart attack, remains a leading cause of death worldwide. While we know that heart tissue dies during an AMI, the specific pathways of "regulated cell death" are still being mapped.

A major piece of this puzzle is ALDH2, an enzyme primarily known for detoxifying aldehydes (and for causing the "Asian Glow" when mutated). The ALDH2*2 variant is one of the most common genetic polymorphisms in humans, affecting roughly 8% of the global population and 40% of East Asians. Carriers of this variant have a significantly higher risk of heart failure post-AMI, but the underlying reason has remained elusive. Most researchers assumed it was simply due to a buildup of toxic aldehydes. This paper investigates whether another mechanism—specifically ferroptosis (cell death caused by iron and lipid peroxidation)—is the real culprit and how ALDH2 regulates it.

Methods

The authors employed a multi-disciplinary approach combining clinical observation with deep molecular biology:

  • Human Cohort Study: They analyzed 177 Chinese patients with acute heart failure, comparing clinical outcomes and blood biomarkers between ALDH2 wild-type and ALDH2*2 carriers.
  • Animal Models: They used "knock-in" mice carrying the ALDH2*2 mutation and performed surgery to simulate a heart attack (LAD ligation).
  • Advanced "Omics": To see what was happening at the molecular level, they used mass spectrometry-based lipidomics and metabolomics to track oxidized fats and antioxidants.
  • Translation Profiling: To understand how proteins were being built, they used Ribo-Lace (Ribo-seq) and polysome profiling, which allowed them to see exactly which mRNAs were being actively translated by ribosomes.
  • Protein Interaction: Co-immunoprecipitation (Co-IP) and Gromacs-based molecular modeling were used to prove that ALDH2 physically binds to eIF3E, a subunit of the protein-starting machinery in the cell.

Datasets

The study relied on primary experimental data rather than public repositories:

  • Clinical Dataset: A cohort of 177 acute heart failure patients from Changhai Hospital, Shanghai.
  • Lipidomic/Metabolomic Profiles: Custom datasets generated from human plasma, mouse serum, and mouse heart tissues.
  • Proteomic/Interaction Data: A list of ALDH2-interacting proteins identified via mass spectrometry (referenced as Table S1).

Key Insights and Ideas

  • The Translation Switch: The most striking finding is that ALDH2 isn't just an enzyme; it's a regulator of protein synthesis. It physically binds to eIF3E. In healthy cells, this interaction keeps the translation of pro-ferroptosis genes in check.
  • ALDH2*2 is a Double Whammy: The mutation doesn't just make the enzyme less active; it leads to significantly lower levels of the ALDH2 protein itself. This "deficiency" frees up eIF3E to aggressively translate mRNAs for TFRC (which brings iron into the cell) and ACSL4 (which prepares fats for peroxidation).
  • Ferroptosis as the Primary Driver: The study shows that the heart damage in ALDH2*2 carriers is specifically ferroptotic. By using a ferroptosis inhibitor (Ferrostatin-1), the researchers were able to "rescue" the heart function in mutant mice, suggesting a clear therapeutic path.
  • Biomarker Signature: The researchers identified a specific "fingerprint" in the blood of ALDH2*2 patients: high levels of oxidized phospholipids and low levels of antioxidants like Coenzyme Q10 and BH4.

Key Results

  • Clinical Severity: Human ALDH2*2 carriers showed significantly higher levels of BNP (a heart failure marker) and lower Ejection Fractions (EF) compared to wild-type patients.
  • Protein Upregulation: In the infarct (damaged) area of ALDH22 hearts, pro-ferroptosis proteins (TFRC, ACSL4, HMOX1) were significantly increased, even though their mRNA levels stayed the same—proving the regulation happens at the translation* stage.
  • Rescue Effect: Knocking down eIF3E specifically in the cardiomyocytes of ALDH2*2 mice restored heart function and reduced the "scar" size after a heart attack.
  • Quantitative Markers: ALDH2*2 patients had a significantly higher ratio of 14,15-DHET/14,15-EET, a known predictor of mortality in heart failure patients.

Limitations and Future Work

While the study provides a robust mechanism, there are a few areas for further exploration:

  • Acute vs. Chronic: The study focuses heavily on the acute phase (3 to 28 days post-MI). The long-term effects of this translational dysregulation over years of heart remodeling remain to be seen.
  • Drug Development: While Ferrostatin-1 worked in mice, it is not currently a clinical drug for humans. Future work is needed to develop safe, human-grade ferroptosis inhibitors or small molecules that can stabilize the ALDH2/eIF3E interaction.
  • Broader Application: The authors suggest this mechanism might apply to other cardiovascular diseases where ALDH2 is implicated, such as atherosclerosis or alcohol-induced cardiomyopathy.

Summary updated

Abstract

Abstract BACKGROUND As an iron-dependent form of regulated cell death caused by lipid peroxidation, ferroptosis has been implicated in ischemic injury but the underlying mechanisms in acute myocardial infarction (AMI) remain poorly defined. Acetaldehyde dehydrogenase 2 (ALDH2) catalyzes detoxification of lipid aldehydes derived from lipid peroxidation and acetaldehydes from alcohol consumption. The Glu504Lys polymorphism of ALDH2 (rs671, ALDH2 *2), affecting around 8% world population and 40% East Asians, is associated with increased risk of MI. This study aims to investigate the role of ALDH2 and ferroptosis in MI. METHODS A Chinese cohort of 177 acute heart failure patients with ALDH2 wild type and ALDH2 *2 were enrolled. MI mouse model of left anterior descending coronary artery ligation (LAD) was conducted on wild type, ALDH2 *2, and mice with cardiomyocyte-specific knock down of eukaryotic translation initiation factor 3 subunit E (eIF3E) by adeno-associated virus. The lipid peroxidation products were measured by mass spectrometry-based lipidomics and metabolomics in human plasma and mouse serum samples as well as in mouse heart tissues. RESULTS Human ALDH2 *2 carriers exhibit more severe heart failure post-AMI with features of ferroptosis in blood samples through lipidomic analysis, including increased levels of multiple classes of oxidized phospholipids, and decreased levels of antioxidants, such as Coenzyme Q-10 (Co-Q10) and tetrahydrobiopterin (BH4). Similar features were observed in MI mouse models of ALDH2 *2, whereas ferroptosis inhibition by Fer-1 significantly improved heart functions and reversed ferroptosis markers. Importantly, ALDH2 *2 led to significantly decreased protein levels of ALDH2, whereas ferroptosis related proteins including Transferrin receptor (TFRC), Acyl-CoA synthetase long chain family member 4 (ACSL4), and Heme oxygenase 1 (HMOX1) were upregulated specifically in the infarct heart tissues. Mechanistically, ALDH2 physically interacted with eIF3E to modulate translation of critical proteins involved in ferroptosis, and ALDH2 deficiency in ALDH2 *2 mutant predisposes cardiomyocytes to ferroptosis by promoting Tfrc/Acsl4/Hmox1 translation. Consistently, cardiomyocytes-specific eIF3E knock down restored ALDH2 *2 cardiac function by attenuating ferroptosis in MI. CONCLUSIONS ALDH2 *2 aggravates acute heart failure in MI through promoting cardiomyocytes ferroptosis, and targeting ferroptosis may be a potential therapeutic target for treating AMI, especially for ALDH2 *2 carriers. Clinical Perspective What Is New? ALDH2 *2 mutant aggravates acute heart failure through promoting cardiomyocytes ferroptosis after myocardial infarction. Active translation of proteins critical for ferroptosis predisposes cardiomyocytes of ALDH2 deficiency to ferroptosis through attenuated interactions with elF3E and ALDH2. Targeting ferroptosis induced by ALDH2 deficiency rescued heart functions post-AMI. What Are the Clinical Implications? Circulating oxidized phospholipids and other features associated with ferroptosis may serve as markers for AMI, especially for ALDH2 *2 carriers. Inhibiting ferroptosis is a viable cardioprotective therapeutic strategy for MI injury particularly for ALDH2 *2 carriers.
BibTeX
@misc{chen2024aldh,
  author = {Xin Chen and Xiujian Yu and Xiaodong Xu and Rui Li and Ningning Liang and Lili Zhang and Luxiao Li and Jingyu Zhang and Mingyao Zhou and Tongwei Lv and Haoran Ma and Yongqiang Wang and Yanwen Ye and Chunzhao Yin and Shiting Chen and Hui Huang and Jinwei Tian and Aijun Sun and Weiyuan Wang and Dewen Yan and Pan Li and Huang‐Tian Yang and Shanshan Zhong and Huiyong Yin},
  title = {{ALDH2/eIF3E Interaction Modulates Protein Translation Critical for Cardiomyocyte Ferroptosis in Acute Myocardial Ischemia Injury}},
  year = {2024},
  doi = {10.1101/2024.08.19.24312276},
  howpublished = {medRxiv},
}
Figure